Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

Fig. 2

RT and IT-IC produced an in situ vaccination response in mice bearing NXS2 neuroblastoma. Intradermal NXS2 tumors (average starting size of 155 mm3 on day 15 post tumor cell implantation) were untreated or treated with IT-IC alone, 12 Gy alone, or 12 Gy and IT-IC. Tumor growth (a) and survival (b, p values are indicated in the table) curves are shown for each treatment group, with disease-free mice at day 60 denoted as complete responses (CR)

Back to article page